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Gene expression profiling of breast 
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Claude Chelala5, Rose-Mary Boustany1,6,* & Arafat Tfayli7,*
Breast cancer is commonest cancer in women worldwide. Elucidation of underlying biology and 
molecular pathways is necessary for improving therapeutic options and clinical outcomes. Molecular 
alterations in breast cancer are complex and involve cross-talk between multiple signaling pathways. 
The aim of this study is to extract a unique mRNA fingerprint of breast cancer in Lebanese women using 
microarray technologies. Gene-expression profiles of 94 fresh breast tissue samples (84 cancerous/10 
non-tumor adjacent samples) were analyzed using GeneChip Human Genome U133 Plus 2.0 arrays. 
Quantitative real-time PCR was employed to validate candidate genes. Differentially expressed genes 
between breast cancer and non-tumor tissues were screened. Significant differences in gene expression 
were established for COL11A1/COL10A1/MMP1/COL6A6/DLK1/S100P/CXCL11/SOX11/LEP/ADIPOQ/
OXTR/FOSL1/ACSBG1 and C21orf37. Pathways/diseases representing these genes were retrieved 
and linked using PANTHER®/Pathway Studio®. Many of the deregulated genes are associated with 
extracellular matrix, inflammation, angiogenesis, metastasis, differentiation, cell proliferation and 
tumorigenesis. Characteristics of breast cancers in Lebanese were compared to those of women from 
Western populations to explain why breast cancer is more aggressive and presents a decade earlier in 
Lebanese victims. Delineating molecular mechanisms of breast cancer in Lebanese women led to key 
genes which could serve as potential biomarkers and/or novel drug targets for breast cancer.
Breast cancer (BC) is the most common cancer in women, accounting for 23% of all female cancers worldwide1. 
Globally, about 1.38 million women are diagnosed with BC and 458,503 die from the disease every year2. Also, 
BC incidence has shown an alarming increase worldwide3. In Lebanon, BC is the leading cancer among women4. 
Since early diagnosis and effective treatments are of great importance in reducing mortality of BC, researchers 
have been trying to identify additional biomarkers and novel drug targets5,6. An important risk factor is human 
epidermal growth factor (HER-2/neu)7. BC patients in Lebanon tend to present with an earlier age at diagnosis, 
52 years compared to 63 years for counterparts in the West, including the United States8,9. This is consistent with 
data from Saudi Arabia10 and China11, providing additional evidence for the higher proportion of young BC in 
Asia than in Western countries. Usually, young BCs tend to have more aggressive biological behavior and clinical 
association with unfavorable prognosis compared with the disease arising in older women12. Young women with 
BC tend to have more advanced tumor TNM staging, more invasive pathological type, higher tumor grade, higher 
rates of lymph node positivity, higher proportion of triple-negativity, higher HER2 expression and lower ER/PR 
positivity11. Indeed, Lebanese BC patients tend to present with larger tumor size, more lymph node involvement, 
and higher tumor grades9. This may be accounted for by both environmental and genetic differences. A better 
understanding of the biology and molecular pathways for this disease is needed in order to tailor therapeutic 
options for this population.
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Based on gene expression analysis, Perou et al. propose that BCs can be divided into the following classes: 
Luminal A [Estrogen Receptor Positive (ER+ ); low grade], luminal B (ER+ ; high grade), HER2 positive 
(HER2-amplification), and basal [ER− ; Progesterone Receptor Negative (PR− ); HER2− ]13. These subclasses dif-
fer significantly in their prognosis and responsiveness to various therapeutic options.
Microarray technology is an effective tool to uncover global changes in the incidence and development of 
cancer14. The application of gene expression profiling is an excellent approach towards integrating the multiple 
molecular events and mechanisms by which cancer may develop15. The oncogenesis process involves the disrup-
tion of diverse cellular pathways including cell cycle, growth, survival and apoptosis. Gene expression microar-
rays allow the concurrent analysis of thousands of genes in a particular tumor providing a detailed description of 
the molecular fingerprint of the tumor.
In this study, differentially expressed genes (DEGs) from BC and normal tissue samples obtained at surgery 
were uncovered, allowing the extraction of a unique mRNA fingerprint of BCs in Lebanese women. PANTHER 
and Pathway Studio® aided in constructing protein-protein interaction networks and highlighted significant 
pathways and novel target genes for the diagnosis of BC in Lebanese women. Moreover, characteristics of BCs in 
Lebanese women were compared to those of women from western populations in an attempt to shed light on why 
BC presents a decade earlier in Lebanese BC victims.
Results
Identification of differentially expressed genes (DEGs). We used Affymetrix GeneChip Human 
Genome U133 Plus 2.0 expression arrays to determine differences in gene expression in 84 cases of invasive 
BC tissue compared to 10 non-tumor adjacent fresh breast tissue samples. Limma package in R was utilized to 
identify the DEGs between BC and non-tumor adjacent samples. Using an adjusted P < 0.05, 3053 genes were 
identified that were differentially expressed between tumor and non-tumor adjacent breast tissue. Among these, 
1076 were up- and 1977 were down-regulated genes (see Supplementary Tables S1 and S2).
Functional gene ontology analysis of breast tumor differentially expressed genes (DEGs). To 
understand relevance of these genes, a program based on Gene Ontology (GO) categories of protein class and 
molecular function was employed. Figure 1 shows the main functional GO categories of transcripts that were 
differentially expressed between tumor and non-tumor breast tissue (adjusted P < 0.05; gene count > 2 of the 
up- or down-regulated genes). Altered transcription of genes in the “protein class” category included a mul-
titude of genes serving as signaling molecules or receptors (Fig. 1a,b; see Supplementary Table S3), and in the 
“molecular function” category, genes were mainly related to binding, receptor and catalytic activities (Fig. 2a,b; 
Figure 1. Pie chart representation of Gene Ontology (GO) for genes differentially expressed in microarray 
analyses and summarized according to protein class, in Lebanese population. Gene expression in tumor 
breast tissue was compared to surrounding non-tumor breast tissue, and the criterion for differential expression 
was choosing the top 50 fold changes with an adjusted P < 0.05, and a gene count > 2 of the DEGs. Functional 
categories of DEGs were obtained using GO annotations from PANTHER classification system.
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see Supplementary Table S3). The upregulated genes included Inhibin Beta A (INHBA), Wnt-1 Inducible 
Signaling Pathway Protein 1 (WISP1), S100 Calcium-Binding Protein P (S100P), Chemokine (C-X-C Motif) 
Ligand 9/10/11 (CXCL9/10/11), Collagen Type X Alpha 1 (COL10A1), Collagen Type XI Alpha 1 (COL11A1), 
Tumor Necrosis Factor Superfamily Member 4 (TNFSF4), NADPH Oxidase 4 (NOX4) and C-Type Lectin 
Domain Family 5 Member A (CLEC5A). The downregulated genes included Proenkephalin (PENK), Tachykinin 
Precursor 1 (TAC1), Delta-Like 1 Homolog (DLK1), c-Fos Induced Growth Factor (FIGF), Oxytocin Receptor 
(OXTR), Doublecortin (DCX), Parathyroid Hormone-Like Hormone (PTHLH), Protein Tyrosine Phosphatase 
Receptor-Type Z Polypeptide (PTPRZ1) and Collagen Type VI Alpha 6 (COL6A6).
Protein-Protein Interaction (PPI) network of DEGs derived from breast cancer. Using a strin-
gency ≥ ± 2-log2 fold change in expression, the 3053 DEGs initially identified between tumor and non-tumor 
breast tissue were narrowed down, to only 170 DEGs, including 36 upregulated genes and 134 downregulated 
genes. To gain insight into how these DEGs affected cellular biological activity, a full overview of their interactions 
with each other was constructed to provide important clues of their functions. The gene or protein hubs with 
genes or proteins with high connectivity degree were identified (see Supplementary Fig. S1). A total of 8 gene 
hubs (red) were selected from the upregulated PPI network, which included INHBA, Matrix Metallopeotidase 
12/13 (MMP12/13), CXCL9/10/11, COL10A1 and Secreted Phosphoprotein 1 (SPP1). Meanwhile, 6 gene hubs 
(green), such as DLK1, PTHLH, TAC1, Adiponectin C1Q and Collagen Domain Containing (ADIPOQ), Leptin 
(LEP) and FIGF, were identified from the downregulated PPI network.
Breast cancer DEGs common to all tumor grades. The data generated established significant differ-
ences in the expression of several genes in normal non-tumor adjacent samples vs. different tumor grades (grade 
I, II and III). Figure 3 demonstrates Venn diagrams (a and b) and a 2-D heat-map (c) of 41 DEGs considered 
significant only if they were up- or down-regulated by ≥ ± 3-log2 fold change in response to cancer (adjusted 
P < 0.05). 2245 DEGs were upregulated in all 3 grades combined together (grade I, II and III), compared to only 
1470 downregulated DEGs. Among these, 811 upregulated DEGs were common to all 3 grades, and only 174 
DEGS were downregulated. Interestingly, grade II induced the highest number of upregulated DEGs, followed 
by grade III, and the lowest number of upregulated DEGs was induced by grade I (Fig. 3a). A number of Integrin 
signaling pathway DEGs including COL11A1 and COL10A1 were upregulated. MMP1/13 were also robustly 
upregulated in all tumor grades, suggesting that BC may have led to an upregulation of genes involved in the 
plasminogen activating cascade and Alzheimer disease-presenilin pathway (Fig. 3c, adjusted P < 0.05). The larg-
est number of downregulated DEGs was induced in grade III, followed by grade II and grade I tumors (Fig. 3b). 
In all tumor grades, a significant reduction in the expression of COL6A6, DLK1, PENK and OXTR involved in 
Figure 2. Pie chart representation of Gene Ontology (GO) for genes differentially expressed in microarray 
analyses and summarized according to molecular function, in Lebanese population. Gene expression in 
tumor breast tissue was compared to surrounding non-tumor breast tissue, and the criterion for differential 
expression was choosing the top 50 fold changes with an adjusted P < 0.05, and a gene count > 2 of the DEGs. 
Functional categories of DEGs were obtained using GO annotations from PANTHER classification system.
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inflammation, angiogenesis, enkephalin release and oxytocin receptor mediated signaling pathway, respectively, 
were identified (Fig. 3c, adjusted P < 0.05).
Expression of breast cancer-induced DEGs common to all molecular subtypes. Similarly, the 
data established significant differences in the expression of several genes in normal non-tumor samples vs. differ-
ent molecular subtypes (Normal-like, Basal, Luminal A, Luminal B and HER-2). Figure 4 shows Venn diagrams 
(a and b) and 2-D heat-maps (c) of 55 DEGs considered significant if they were up- or down-regulated by 
≥ ± 3-log2 fold change in response to cancer (adjusted P < 0.05). 3927 DEGs were upregulated in all 5 molec-
ular subtypes combined together (Normal-like, Basal, Luminal A, Luminal B and HER-2), compared to 4262 
downregulated DEGs. Among these, a total of 87 upregulated DEGs were common to all 5 molecular subtypes, 
and only 9 DEGS were downregulated in the 5 molecular subtypes. Interestingly, HER-2 and Luminal B types 
induced the highest number of up- or down-regulated DEGs, followed by Basal and Luminal A. Not surprisingly, 
the lowest number of upregulated DEGs was induced in Normal-like subtype (Fig. 4a). Integrin signaling path-
way DEGs included COL11A1 and COL10A1. MMP1/9 were also robustly upregulated in 4 molecular subtypes 
(Luminal A, Luminal B, HER2 and Basal), suggesting that BC may have led to an upregulation of genes involved 
in the Alzheimer disease-presenilin pathway (Fig. 4c, adjusted P < 0.05). The highest number of downregulated 
DEGs was induced in HER-2 and Luminal B types, followed by Basal and Luminal A. The lowest number of 
downregulated DEGs was observed in Normal-like subtype (Fig. 4b). A significant reduction in the expression 
of COL6A6 and Prostaglandin-Endoperoxide Synthase 2 (PTGS2) involved in inflammation and in DLK1 and 
Secreted Frizzled-Related Protein 1 (SFRP1) both involved in angiogenesis was observed in the 4 molecular sub-
types,. As expected, the expression of significant DEGs was very similar between the Normal-like subtype and 
non-tumor adjacent samples (Fig. 4c, adjusted P < 0.05).
Validation of microarray analysis results with qRT-PCR. Seven genes were randomly chosen for further 
analysis by qRT-PCR based on biological relevance. Results exhibited consistency with those of microarray analysis, 
validating our findings. Tumor status induced a significant decrease in the expression of FIGF (P < 0.0001), 
ADIPOQ (P < 0.0001), LEP (P = 0.0009), PTHLH (P = 0.0345) and FOS-like Antigen 1 (FOSL1; P < 0.0001) 
compared with expression in corresponding non-tumor tissue (Fig. 5a). There was also a significant increase in 
Figure 3. Differentially expressed genes shared by all tumor grades, in Lebanese population. Venn diagram 
displaying numbers of (a) upregulated and (b) downregulated DEGs in either grade I, grade II or grade III 
tumors. (c) 2-dimentional heat map of 41 DEGs. Heat map of mRNA abundance intensities of the differentially 
expressed genes in the profiled samples. RMA preprocessed data was transformed to z-scores. The legend 
represents relative over- (red) and under-expression (green). The labeling at the bottom represents the normal 
samples (N) and patients grouping by grade (1, 2 and 3). Adjusted P < 0.05, stringency ≥ ± 3-log2 fold change in 
expression.
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the expression of MMP13 (P = 0.0169), S100P (P = 0.0234) and COL10A1 (P = 0.024) compared with expression 
in the corresponding non-tumor tissue (Fig. 5b).
Comparison analysis of DEGs in Lebanese and Western populations. Limma package in R was 
utilized to identify the DEGs between BC and non-tumor adjacent samples, in Lebanese and Western popula-
tions. Using an adjusted P < 0.05 and a stringency ≥ ± 1-log2 fold change in expression, 1911 significant genes 
were identified that were differentially expressed between tumor and non-tumor breast tissue in both population 
datasets. Thirty-two genes found in the overlapping region were common to the two datasets, implying that 
these genes were differentially expressed in both Lebanese and Western patients (Fig. 6a). Seventeen of these 32 
genes were commonly over- or underexpressed in both populations (Fig. 6b), whereas the remaining 15 genes 
were dysregulated in opposing directions. Among those 15 genes, the most commonly highly up- or downregu-
lated were G Protein-Coupled Receptor, Class C, Group 5, Member A (GPRC5A), Peptidase Domain Containing 
Associated With Muscle Regeneration 1 (PAMR1), Teashirt Zinc Finger Homeobox 2 (TSHZ2), Lymphatic Vessel 
Endothelial Hyaluronan Receptor 1 (LYVE1) and Thrombospondin Receptor (CD36) (Fig. 6c). There were 1879 
differentially expressed candidate genes appearing exclusively in either Western or Lebanese patients, as depicted 
by the Venn diagram (Fig. 6a). Among these, 1166 and 713 DEGs were exclusive genes in either Western or 
Lebanese populations, respectively. These mutually exclusive genes drew our attention since they might reflect the 
differences between the two populations, and may potentially influence the BC in the two populations. Further 
details about the most significant exclusive genes in each population are shown in Supplementary Tables S1, S2 
and S4.
Discussion
Early detection and accurate diagnosis are an effective method to lower mortality of BC. The identification of 
molecular subtypes and the development of prognostic and predictive molecular signatures through gene expres-
sion profiling have resulted in a better appreciation of the biologic heterogeneity of BC16.
mRNA expression levels in BC fresh tissue samples were determined and association with patient clinical 
characteristics examined. 3053 DEGs including 1076 up-regulated and 1977 down-regulated DEGs were identi-
fied. Classification of Lebanese tumor samples was assessed by differences in gene expression patterns into differ-
ent molecular subtypes13: Luminal A (35%), luminal B (24%), HER2 positive (17%), basal (14%) and normal-like 
Figure 4. Differentially expressed genes shared by all molecular subtypes, in Lebanese population. Venn 
diagram displaying numbers of (a) upregulated and (b) downregulated DEGs in 5 different molecular subtypes 
(Normal-like, Basal, Luminal A, Luminal B and HER2). (c) 2-dimentional heat map of 55 DEGs. Heat map of 
mRNA abundance intensities of the differentially expressed genes in the profiled samples. RMA preprocessed 
data was transformed to z-scores. The legend represents relative over- (red) and under-expression (green). The 
labeling at the bottom represents the normal samples and patients grouping by PAM50 molecular subtype. 
Adjusted P < 0.05, stringency ≥ ± 3-log2 fold change in expression.
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(9%). A distribution of breast cancer subtypes is similar to what is reported in western populations17. Lebanese 
women have tumors with similar gene expression patterns in luminal A, luminal B, basal and HER2 subtypes to 
those in women in the west. GATA-binding protein 3 (GATA3) and Estrogen Receptor 1 (ESR1) were significantly 
upregulated in Lebanese luminal A and B, the only ER+ subtypes. Keratins 8/18 (KRT8/18), characteristic of 
luminal epithelial cells, are significantly overexpressed in Lebanese luminal B tumors. Keratins 5/17 (KRT5/17) 
characteristic of basal epithelial cells are significantly under-expressed in Lebanese luminal A/B tumors. HER2/
neu or Erb-B2 is significantly overexpressed in Lebanese HER2 positive breast tumors. Keratin 6 (KRT6) was 
significantly up-regulated in Lebanese basal subtype, whereas KRT8, GATA3 and X-box binding protein 1 (XBP1) 
were significantly down-regulated.
Most up-regulated DEGs were involved in pathways of Integrin signaling and presenilin. Down-regulated 
DEGs were involved in inflammation and angiogenesis. COL11A1, COL10A1, MMP1, COL6A6 and DLK1 genes 
were identified in the Lebanese cohort (Fig. 7).
A number of genes differentially expressed (non-tumor adjacent tissue vs. BC tissue) are related to extra-
cellular matrix (ECM), including COL11A1, COL10A1 and COL6A6. These proteins maintain integrity of tis-
sues including muscle, tendons, skin, cartilage, and intervertebral disks18. In invasive carcinomas, extracellular 
collagens are key to tumor behavior and are subject to continuous remodeling, inhibiting and/or promoting 
tumor progression, according to stage of tumor development19. Related pathways are PI3K-Akt and ERK sign-
aling. COL11A1 encodes a minor collagen found in many tissues and dysregulated in breast and colon cancer20. 
COL10A1 encodes a short chain collagen expressed by hypertrophic chondrocytes during endochondral ossifi-
cation. Its expression is elevated in diverse solid tumor types and is associated with tumor vasculature21. Tissues 
analyzed demonstrated significant up-regulation of COL11A1 and COL10A1 in tumor tissue as compared to 
non-tumor adjacent tissue in the Lebanese, suggesting that both proteins might play a role in local invasion of BC 
Figure 5. Validation of microarray analysis results with qRT-PCR, in Lebanese population. Relative 
mRNA expression was measured by quantitative RT-PCR. (a) The following underexpressed genes were 
randomly chosen: FIGF (P < 0.0001), ADIPOQ (P < 0.0001), LEP (P = 0.0009), PTHLH (P = 0.0345) and 
FOSL1 (P < 0.0001). (b) The following overexpressed genes were randomly chosen: MMP13 (P = 0.0169), 
S100P (P = 0.0234) and COL10A1 (P = 0.024). Values are means of the fold changes normalized to PGK1 
mRNA expression, with their standard errors represented by vertical bars. *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001 by Student’s t-test (n = 27).
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cells. Altered expression of COL11A1/COL10A1 is associated with tumor development/progression. Several stud-
ies reported that COL11A1 is overexpressed in invasive ductal carcinoma (IDC) of the breast relative to ductal 
carcinoma in situ (DCIS) in Spanish populations. This overexpression is correlated with carcinoma aggressive-
ness, progression, and lymph node metastasis22. Chang et al. report that COL10A1, MMP13, CAMP and FLJ25416 
are overexpressed in human BC tissues in the Taiwanese23. Collagen VI (COL6) up-regulation is reported in 
various aspects of tumor progression. Several malignant cancer cell lines express COL6 including those derived 
from mammary gland, colon, pancreatic ductal adenocarcinomas and hepatocarcinoma24. COL6A6, a form of 
COL6, is expressed in a wide range of fetal and adult brain, heart and muscle25. COL6A6 is increased in Ullrich 
congenital muscular dystrophy26. COL6A6 is downregulated in tumor tissue versus adjacent normal breast tissue 
in the Lebanese.
Human MMP proteins include 24 members27 function in breakdown of extracellular matrix in nor-
mal physiological processes of embryonic development, wound healing, and tissue remodeling, and play an 
important role in arthritis, cancer infiltration, metastasis and angiogenesis23. MMP1 (collagenase-1)/MMP8 
(collagenase-2)/MMP13 (collagenase-3) can break down collagen types I, II, III and V. MMP13 is overexpressed 
in human BC tissues, in Danish and Taiwanese populations, and imply that in the process of BC turning from 
ductal carcinoma in situ to invasive ductal carcinoma, MMP13 can break down basement membranes resulting 
in invasive cancer23,28. MMP1 is highly expressed in many types of cancer, specifically BC in Western populations, 
and positively correlates with accelerated cell migration, advanced clinical stage and metastasis in BC, making 
MMP1 a significant predictor of poor prognosis in BC29.
DLK1, a member of the EGF-like repeat-containing family of proteins, includes NOTCH receptors and lig-
ands. DLK1 is involved in differentiation, cell proliferation and tumorigenesis. DLK1 may function both as onco-
genic and anti-oncogenic30. Kawakami et al. indicate that expression of DLK1 was lost in primary renal cell 
carcinoma (RCC) compared to adjacent normal kidney tissue in the Japanese and show tumor growth to be 
blocked by restoration of DLK1 compared to control cells suggesting that DLK1 has tumor suppressor activity 
in RCCs in vitro and in vivo31. Human DLK1 was also expressed in colon, breast, pancreas and lung carcinoma 
in vitro32.
Figure 6. Comparative analysis of DEGs in Western and Lebanese datasets. In order to compare the 
difference of DEGs selected in Western and Lebanese populations datasets, gene expression in tumor breast 
tissue was compared to surrounding non-tumor breast tissue in both populations, and the criterion for 
differential expression was an adjusted P < 0.05, and a stringency ≥ ± 1-log2 fold change in expression. (a) A 
total number of 1911 genes were left, among which 1166 and 713 genes were exclusive for the Western and 
Lebanese populations, respectively. Only 32 genes were found in the overlapping region, so were common to 
both datasets. (b) List of the 17 genes that are commonly over- or underexpressed in both populations. (c) List 
of the 15 genes and their log2 fold changes that are differentially expressed in both populations, but in opposing 
directions.
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Our data also demonstrates significant up-regulation of COL11A1, COL10A1, MMP1 and MMP13, and sig-
nificant down-regulation of COL6A6 and DLK1 in tumor relative to non-tumor adjacent breast tissue. COL11A1, 
COL10A1, MMP1 and MMP13 are highly expressed in aggressive molecular subtypes (basal and HER2 tumors) 
in the Lebanese as their expression increases tumor migration and proliferation. COL11A1, COL10A1, MMP1, 
and DLK1 are known to play a role in BC and tumorigenesis, but not COL6A6. So, COL6A6 may be a potential 
novel biomarker for BC in Lebanese women. Further studies are needed before considering expression of these 
genes in decisions of treatment and whether considering them as targets for therapy or as prognostic factors.
Significant differences in tumor vs. non-tumor adjacent tissue regarding expression of several other genes 
were established in the Lebanese. S100P, CXCL11, and SRY (Sex Determining Region Y)-Box 11 (SOX11) display 
higher expression in tumor samples. LEP, ADIPOQ, and OXTR manifest lower expression in tumor samples.
Several studies from Germany reported overexpression of S100P in BC, among other cancers33. In addition to 
their function as mediators of inflammatory responses, chemokines are involved in the regulation of tumor devel-
opment and metastasis. Levels of the three chemokines CXCL9, CXCL10 and CXCL11 were markedly higher in 
metastatic BC patients as compared to healthy control sera, in the West34. Liu et al. demonstrated that expression 
of SOX11 in BC tissues was significantly higher than in normal tissue, in the Chinese. This overexpression is cor-
related with smaller tumor size and milder tumor grade, indicating that SOX11 could inhibit growth and progres-
sion of BC, and promote absence of lymph node metastasis35. Both LEP and ADIPOQ are adipokines secreted by 
adipocytes. LEP has been directly associated with obesity, while ADIPOQ has been inversely associated with obe-
sity and visceral fat accumulation. Basu et al. demonstrated that both LEP and ADIPOQ are expressed at higher 
levels in normal adjacent breast tissue compared to tumor specimens, in the French population36. The hormone 
oxytocin is common in cells of healthy breast tissue, but is rarely or never detected in BC in vitro and in vivo. 
Oxytocin inhibits proliferation of human BC cell lines, and thus may play a role in preventing this disease37.
In clinical practice, the elucidation of the association between gene expression profiles and clinico-pathological 
characteristics may aid physicians in selecting patient-suitable treatments. Good biomarkers can aid in early can-
cer screening, confirm cancer diagnosis, predict outcome, tailor therapy, and guide future research directions by 
shedding light on new tumorigenesis pathways. In this study, when comparing gene expression between BC tissue 
Figure 7. Functional relationship network of DEGs between tumor and non-tumor adjacent breast tissue, 
in Lebanese population. Pathway Studio® generated network interactions between most significant DEGs 
in breast tissue (Adjusted P < 0.05, stringency ≥ ± 2-log2 fold change in expression). Upregulated genes are 
designated in red and downregulated genes in green.
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and adjacent non-tumor tissue, no significant association with the following clinical variables was determined: 
age, menopausal status, lower or higher tumor grade, molecular subtype, HER2 expression, or family history of 
BC (see Supplementary Figs S2 and S3). Whereas, our findings confirm a significant association in Lebanese BC 
patients between the expression levels of FOSL1, Acyl-CoA synthetase bubblegum family member 1 (ACSBG1), 
and Chromosome 21 open reading frame 37 (C21orf37) genes with ER/PR expression and family history of 
ovarian cancer. This suggests the possible usefulness of including them as biomarkers in BC diagnostics. The 
3 genes (FOSL1, ACSBG1, and C21orf37) were downregulated in our patients with ER-negative BCs (log2-fold 
change: − 0.37; − 0.16; − 0.34; adjusted P < 0.05), and PR-negative BCs (log2-fold change: − 0.28; − 0.15; − 0.18; 
adjusted P < 0.05); and upregulated in patients having a family history of ovarian cancer (log2-fold change: 1.08; 
0.5; 0.8; adjusted P < 0.05). Hormone receptor-negative tumors have a higher chance of recurrence than hormone 
receptor-positive tumors in the first five years after diagnosis. After five years, this difference decreases and over 
time, goes away38. Having a family history of ovarian cancer increases the chances of getting breast or ovarian 
cancer. Such knowledge has great potential in preventive strategies, particularly for women with family history of 
ovarian cancer who are at high risk, and for women with ER/PR-negative BCs. FOSL1 is downregulated in breast 
tumor tissues, in our cohort. In high-grade cases of BC tissue, low expressions of genes involved in apoptosis, cell 
cycle control and immune pathways are reported. These include the FOSL1 gene39. Acyl-CoA synthetases (ACSs) 
that catalyze the conversion of fatty acids to their active form acyl-CoAs play a central role in fatty acid metab-
olism. ACS bubblegum (ACSBG) is one subfamily containing ACSBG1 and ACSBG2 isozymes40. Several studies 
suggest that ACSBG1 may be involved in the biochemical pathology of X-linked adrenoleukodystrophy (X-ALD). 
Patients with X-ALD have neurodegeneration and elevated serum and tissue levels of saturated very long-chain 
fatty acids. In mice, ACSBG1 is highly expressed in the brain, adrenal cortex, and testis41. We suggested, for the 
first time, the involvement of the ACSBG1 gene in BC in Lebanese cases, making it a potential novel gene for BC 
prognosis in Lebanese women. Also, nothing is known about C21orf37 gene and its association with cancer, mak-
ing it a possible gene or biomarker in BC in the Lebanese. Further investigations are needed to validate whether 
these genes can serve as targets for therapy or as prognostic factors in Lebanese BC.
Our comparative analysis showed that most of the genes exclusively dysregulated in Western populations 
were involved in signaling pathways of Integrin and inflammation mediated by chemokine and cytokine. Genes 
including LIM and Senescent Cell Antigen-Like Domains 1 (LIMS1) and Platelet Factor 4 Variant 1 (PF4V1) 
were significantly identified in these pathways (see Supplementary Table S4). LIMS1, a protein containing 5 LIM 
domains or double zinc fingers, plays a role in integrin-mediated cell adhesion or spreading. It is also known to 
be involved in the regulation of cell survival, cell proliferation and cell differentiation. LIMS1 was significantly 
upregulated in tumor tissue in Western populations, which is in agreement with its anti-apoptotic role in can-
cer (log2-fold change: 3.05; adjusted P < 0.05). Angiogenesis, the formation of an ever more branching network 
of blood vessels from a pre-existing vascular network, has been established as a requisite for successful tumor 
growth and cancer progression42. PF4V1 also known as CXCL4L1, displays a strong anti-angiogenic function and 
thus impairs tumor growth. In fact, Van Raemdonck et al. showed that platelet-derived CXC chemokines, CXCL4 
and CXCL4L1, inhibited lymphatic endothelial cell proliferation in vitro, reduced proliferation of MDA-MB-231 
cells in vitro and decreased MDA-MB-231 tumor growth in vivo43. The anti-tumoral activity of PF4V1 via inhibi-
tion of angiogenesis and induction of apoptosis within tumor tissue was confirmed by the significant downregu-
lation of this gene expression in tumor tissue of Western populations (log2-fold change: − 3.20; adjusted P < 0.05).
Nevertheless, among the exclusively dysregulated genes in the Lebanese population, we mention COL11A1, 
COL10A1, MMP1 and MMP13 that were significantly upregulated in breast tumor tissue compared to adjacent 
non-tumor tissue, making BC in this population more aggressive with increased tumor migration and prolifer-
ation. Also, levels of the three chemokines CXCL9, CXCL10 and CXCL11 were markedly higher, exclusively in 
Lebanese tumor tissue as compared to non-tumor breast tissue, making BC in this population prone to metastasis 
(see Supplementary Tables S1 and S2).
Of the 17 genes that were significantly overexpressed in both Western and Lebanese populations, we mention 
Cyclin Kinase Subunit 2 (CKS2), Forkhead Box M1 (FOXM1), and Src Homolog and Collagen Homolog Binding 
Protein 1 (SHCBP1) (Fig. 6b). CKS2 protein is essential for the first metaphase/anaphase transition of mammalian 
meiosis. It is known to be up-regulated in various malignancies including breast cancer tissue, suggesting that 
CKS2 may be an oncogene44. FOXM1 is ubiquitously expressed in cells undergoing proliferation, and overex-
pression of FOXM1 is associated with poor prognosis in various malignant tumors including breast cancers45. 
SHCBP1 is shown to be significantly up-regulated in breast cancer tissues compared with adjacent normal tissues, 
and its overexpression is correlated with advanced clinical stage and poorer survival46. Whereas, Adiponectin 
(ADIPOQ) and Sarcoglycan Epsilon (SGCE) were significantly under-expressed in both populations (Fig. 6b). 
Basu et al. demonstrated that ADIPOQ is expressed at higher levels in normal adjacent breast tissue compared to 
tumor specimens36. Ortega et al. demonstrated that SGCE is significantly downregulated in colorectal tumors47.
Of the 15 genes with opposite dysregulation in both populations, we mention Teashirt Zinc Finger Homeobox 
2 (TSHZ2) and Peptidase Domain Containing Associated with Muscle Regeneration 1 (PAMR1) that were 
significantly upregulated in Western populations but significantly downregulated in the Lebanese (Fig. 6c). 
Carcinogenesis is the result either of the activation of proto-oncogenes or the inactivation of tumor suppressor 
genes. Yamamoto et al. showed, for the first time, that Teashirt Zinc Finger Homeobox 2 (TSHZ2) exhibited con-
sistent diminished expression in many cancer cell lines compared to normal epithelial cells and in 100% of the BC 
clinical cases examined, making it a novel tumor suppressor gene48. Similarly, a recent study showed that Peptidase 
Domain Containing Associated with Muscle Regeneration 1 (PAMR1) expression was reduced in all tested BC cell 
lines, while it was expressed moderately in normal breast tissues and primary mammary epithelial cells. In addi-
tion, ectopic expression of PAMR1 markedly suppressed cancer cell growth, making it a putative BC tumor sup-
pressor49. The downregulation of these two genes may also be observed in several other types of cancers, including 
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prostate cancer. So, the suppression of certain tumor suppressor genes such as TSHZ2 and PAMR1 may be the cause 
of the more aggressive type of BC in Lebanese patients, leading to poor prognosis and an increased risk of death.
On the contrary, G Protein-Coupled Receptor, Class C, Group 5, Member A (GPRC5A) was found to be 
upregulated in Lebanese but under-expressed in Western populations (Fig. 6c). GPRC5A is overexpressed in 
breast, colon and gastric cancers50, with the caveat that GPRC5A, among 80 genes, was significantly up-regulated 
in young BC patients (aged ≤ 45 years) relative to older, post-menopausal BCs (aged ≥ 65 years) (Fold change: 
0.67; adjusted P < 0.01)11. When comparing age of diagnosis, the Lebanese population had a larger number of 
young patients, which may explain the upregulation of GPRC5A in our population. More interestingly, a set 
of genes such as CXCL and MMP, were also up-regulated in young patients with BC, in Asian population11. 
Their important roles in cancer cell migration, invasion, and metastasis have been documented51. As mentioned, 
MMP1, MMP13, CXCL9, CXCL10 and CXCL11 were significantly upregulated, exclusively in Lebanese tumor 
tissue compared to adjacent non-tumor tissue (see Supplementary Tables S1 and S2), explaining why Lebanese 
patients diagnosed at a younger age are prone to develop more aggressive BCs with a greater potential for metas-
tasis associated with poor prognosis.
Our findings may support the notion that Lebanese patients are exposed to unique environmental/genetic 
factors. Further investigations are necessary to explore influences other than genetic factors that may correlate 
with behavior of BC in different countries.
In conclusion, several genes associated with BC have been used as diagnostic or prognostic markers, and/
or therapeutic targets worldwide, such as HER252,53. Biomarkers for early diagnosis and therapy of BC are still 
limited. Gene expression microarrays have allowed identification of a differentially regulated subset of genes 
which may play a role in the development of BC in Lebanese women. Findings suggest that expression of func-
tionally related genes and transcription factors are modulated in BC in a population-specific manner, with wider 
implications for all BC patients. Informed speculations about other mechanisms underlying tumorigenesis have 
emerged. Further elucidation of signaling pathways linking genes to tumor behavior may provide key insights 
into molecular mechanisms driving breast tumorigenesis.
Materials and Methods
Subjects and biological sampling. The research protocol was approved by the Institutional Review 
Board (IRB) at the American University of Beirut (AUB), all subjects provided written informed consent, and all 
methods were conducted in accordance with approved guidelines and regulations. Subjects were recruited from 
American University of Beirut Medical Center (AUBMC), between September 2012 and May 2014. The sample 
consisted of 84 subjects (aged 33–84 years) and included female individuals newly diagnosed with stage I, II or III 
BC that were subjected to surgical resection at AUBMC. Exclusion criteria included prior history of malignancies 
or any therapy for BC. Fresh BC and corresponding non-tumor breast samples were also collected and stored in 
RNAlaterTM (Qiagen) at − 20 °C, until further analysis. Normal tissue controls were selected to be as far away as 
possible from the malignant tumor from mastectomy specimens.
Clinical variables. Clinical covariates used in gene expression analysis include age, menopausal status, tumor 
grade, stage, molecular subtype, estrogen receptor (ER) status, progesterone receptor (PR) status, human epider-
mal growth factor receptor 2 (HER2) status, and family history of other cancers (including breast and ovarian 
cancer). Clinical characteristics of the patients are summarized in Supplementary Table S5.
RNA isolation. Using RNeasy® Plus Mini Kit (Qiagen), total RNA was isolated from human fresh breast tissues, 
according to the manufacturer’s protocol and stored at − 80 °C. For assessing RNA quality and yield, A260/A280 and A260/
A230 ratios for RNA were analyzed with ExperionTM Automated Electrophoresis System (BioRad). RNA concentrations 
were determined by absorption at 260 nm wavelength with a ND-1000 spectrometer (Nanodrop Technologies).
Gene expression analysis. A total of 94 fresh breast tissue samples, comprising 84 cancer samples and 10 
adjacent non-tumor samples, were collected and used to represent the Lebanese cohort. Gene expression profiling 
was performed using the GeneChip Human Genome U133 Plus 2.0 arrays (Affymetrix Inc.) representing over 
45,000 transcripts. Briefly, 100 ng of total RNA were amplified, labeled, fragmented and then hybridized using the 
GeneChip 3′ IVT Express Kit as instructed by the manufacturer. After washing and staining, using the GeneChip 
Fluidics Station 450, the arrays were scanned with a GeneChip Scanner 3000 7G. Cell Intensity Data (CEL) files 
were generated using the Affymetrix GeneChip Command Console (AGCC) software version 3.2. Data used to 
represent the Western cohort were downloaded from the NCBI GEO database54. These comprised raw data files 
from two Affymetrix datasets - GSE6519455 and GSE256856.
All data analyses were performed in R (v3.2.2), using Bioconductor (http://www.bioconductor.org) and asso-
ciated packages. After the application of stringent quality control criteria, the data from each cohort was quantile 
normalized independently, using the Robust Multi-array Average (RMA) algorithm57. Differential expression 
analysis between the tumor and normal expression profiles were conducted. First, the mRNA abundance profiles 
of probes representing individual genes were collapsed for each patient, with the mean value used to represent the 
gene expression summary. Genes reported differentially expressed (DE) between the tumor and normal samples 
from each cohort were identified using limma58, which fits a gene-wise linear model to the normalized expression 
values. In addition, the Benjamini and Hochberg’s method was applied to control the false discovery rate (FDR)59, 
with significance thresholds being set at FDR ≤ 0.05 and an absolute log2 fold change of at least 1. Subsequently, 
the lists of DE gene generated from the Lebanese and Western analyses were compared.
Heat maps and Venn diagrams were generated using the R packages gplot and VennDiagram, respectively. 
PANTHER® version 10.0 and Pathway Studio® were used for detection of gene ontology and canonical pathway 
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analysis with significant transcripts in tumor group compared to control. Networks of biologically related genes 
were created using Pathway Studio®.
Quantitative real-time PCR. Confirmation of microarray results was performed by quantitative real-time 
PCR. Total RNA was reverse transcribed using RevertAid Reverse Transcriptase (Thermo Scientific) with 100–
1000 ng of input RNA and random primers (Thermo Scientific). Quantitative real-time PCR reactions were per-
formed in 96-well plates using specific primers (TIB MOLBIOL) and the iQTM SYBR® Green Supermix (BioRad) 
as a fluorescent detection dye, in CFX96TM Real-Time PCR (BioRad), in a final volume of 12.5 μ l. To characterize 
generated amplicons and to control contamination by unspecific by-products, melt curve analysis was applied. 
Each reaction was performed in duplicate. All results were normalized to PGK1 mRNA level and calculated using 
the  Δ Δ Ct method. The specificity of the PCR was determined by melt-curve analysis for each reaction. Primer 
sequences are listed in Supplementary Table S6.
Statistical analysis. mRNA expression was quantified in breast adenocarcinomas compared to nor-
mal tissue. Continuous data was expressed as means ± SEM, and compared by the two-tailed Student’s t-test. 
Gene expression data derived by Affymetrix or quantitative real-time PCR was compared for tumor vs. normal 
non-tumor adjacent tissue by standard t-test.
GraphPad Prism 6 (GraphPad Software, Inc., California, USA) was used for analysis, except for the Affymetrix 
expression data that was analyzed using R statistical environment. All tests were two-sided and an adjusted 
P < 0.05 was considered as a statistically significant difference.
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